CLINICAL RESEARCH
Borelis Pro phytomedicine for the complex treatment of Lyme borreliosis in children
1
Department of Children’s Diseases and Pediatric Surgery, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
2
Pharmacognosy with the Medical Botany Department, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
3
Department of Microbiology, Virology and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
4
Department of Infectious Diseases, Epidemiology and Dermatovenereology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
Submission date: 2022-03-18
Final revision date: 2022-07-19
Acceptance date: 2022-08-14
Publication date: 2022-09-29
Arch Med Sci Civil Dis 2022;7(1):33-36
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Lyme disease, also known as Lyme borreliosis (LB) (tick (Ixodes)borne borreliosis) is a transmissible, natural-focal disease characterized by damage of the skin, nervous system, heart.
Material and methods:
Under observation were 68 children – residents of Ternopil region, who applied to Ternopil Regional Children Hospital, and whose age range was 8–17 years. Two schemes of complex treatment of patients were tested: the 1st – patients received Doxycycline (Unidox Solutab®), tablets 100 mg, 10 pcs. 2 time/day after meals for 14 days at a dose 4 mg/ kg; the 2nd – patients received the treatment regimen like the 1st group and phytomedicine “Boreliss pro” capsules, 28.56g, 60 pcs. (Duo Life Boreliss Pro., Poland) 1 capsule 2 time/day after meals for 14 days.
Results:
Results showed that was significantly (p < 0.05) lower severity of LB in patients who received antibacterial therapy in combination with doxycycline hydrochloride and phytomedicine “Boreliss pro” (1 caps. 2 times/day, after meals), compared with individuals in another group, on the 30th day after treatment. Complex therapy of patients by phytomedicine “Boreliss pro” causes a decrease of pro-inflammatory levels of cytokines IL-1β in the serum.
Conclusions:
Comprehensive treatment of patients with an erythematous form of LB by phytomedicine “Boreliss pro” contributes to a significantly (p < 0.05) faster disappearance of clinical manifestations of LB, shortening the duration of doxycycline hydrochloride use, and reducing the likelihood of side effects from this drug.
Lyme disease, also known as Lyme borreliosis (LB) (tick (Ixodes)borne borreliosis) is a transmissible, natural-focal disease characterized by damage of the skin, nervous system, heart.
Material and methods:
Under observation were 68 children – residents of Ternopil region, who applied to Ternopil Regional Children Hospital, and whose age range was 8–17 years. Two schemes of complex treatment of patients were tested: the 1st – patients received Doxycycline (Unidox Solutab®), tablets 100 mg, 10 pcs. 2 time/day after meals for 14 days at a dose 4 mg/ kg; the 2nd – patients received the treatment regimen like the 1st group and phytomedicine “Boreliss pro” capsules, 28.56g, 60 pcs. (Duo Life Boreliss Pro., Poland) 1 capsule 2 time/day after meals for 14 days.
Results:
Results showed that was significantly (p < 0.05) lower severity of LB in patients who received antibacterial therapy in combination with doxycycline hydrochloride and phytomedicine “Boreliss pro” (1 caps. 2 times/day, after meals), compared with individuals in another group, on the 30th day after treatment. Complex therapy of patients by phytomedicine “Boreliss pro” causes a decrease of pro-inflammatory levels of cytokines IL-1β in the serum.
Conclusions:
Comprehensive treatment of patients with an erythematous form of LB by phytomedicine “Boreliss pro” contributes to a significantly (p < 0.05) faster disappearance of clinical manifestations of LB, shortening the duration of doxycycline hydrochloride use, and reducing the likelihood of side effects from this drug.
REFERENCES (15)
1.
Andreichyn MA. Lyme borreliosis. Diagnostic criteria, treatment and prevention: guidelines. Ternopil TDMU: Ukrmedknyha; 2019.
2.
Nykytyuk SO, Klymniuk SI. Lyme borreliosis in children. Ach Clin Exp Med 2020; 1: 14-25.
3.
Shkilna MI, Marchyshyn SM, Andreichyn MA, et al. Improving the effectiveness of comprehensive treatment of patients with Lyme disease using honey stevia. Ach Clin Exp Med 2020; 1: 195-201.
4.
Cistus [Electronic resource] Gardener’s health. Available from: https://sadovodstvo.in.ua/a296... звернення: 5.08.2021).
5.
Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1 secretion. Cytokine Growth Factor Rev 2011; 22: 189-95.
6.
Goc A, Niedzwiecki A, Rath M. Cooperation of doxycycline with phytochemicals and micronutrients against active and persistent forms of Borrelia sp. Int J Biol Sci 2016; 12: 1093-103.
7.
Shkilna MI, Andreichyn MA, Ivakhiv OL. Dynamics of interleukins in patients with Lyme disease. Med Clin Chem 2020; 22: 17-22.
8.
Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
9.
Piper SC, Ferguson J, Kay L. The role of interleukin-1 and interleukin-18 in proinflammatory and anti-viral responses to rhinovirus in primary bronchial epithelial cells. PLoS One 2013; 8: e63365.
10.
Savych A, Marchyshyn S. Investigation of pharmacological activity the new antidiabetic plant gathering in streptozotocin-nicotinamide-induced diabetes in the rats. Pharma Innov J 2017; 6: 175-7.
11.
Voitsekhivska OV, Sytar OV, Taran NY. Phenolic compounds: developmental activity, biological activity, perspectives of investment. Bull Kharkiv Natl Agrar Univ Series Biol 2015; 1: 104-19.
12.
Kovalev VN, Kislichenko VS, Zhuravel IA, Shmaraeva IE. Promising directions in the study of medicinal plants and the creation of domestic phytopreparations. Pharmacist 1999; 12: 139-40.
13.
Choi DH, Han JH, Yu KH. Antioxidant and anti-obesity activities of polygonum cuspidatum extract through alleviation of lipid accumulation on 3T3-L1 adipocytes. J Microbiol Biotechn 2020; 30: 21-30.
14.
Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011; 2011: 721608.
15.
Soloski MJ, Crowder LA, Lahey LJ, et al. Serum inflammatory mediators as markers of human Lyme disease activity. PLoS One 2014; 9: e93243.
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
